Psychedelic Bulletin #145: MAPS’ Second Phase 3 Study Published; EMA’s New Draft Guideline on Depression Drug Dev Includes Psychedelics; California’s Decrim. Bill Goes to Governor

This Issue: and lots more… MAPS-affiliated researchers published their second Phase 3 study of MDMA-assisted therapy (MDMA-AT) for PTSD last week.The data looks remarkably similar to that produced by the first Phase 3, MAPP1. This paves the way for a New Drug Application submission, which is expected to happen in the coming months. If all goes to plan, we could see an approval next year.Read more…

Source